Group items tagged

The National Institute for Health and Care Excellence (NICE) has published a new diagnostic guidance to enhance CYP2C19 genotype testing to guide clopidogrel use for patients who have suffered an ischemic stroke or transient ischemic attack. Published in July, the diagnostic guidance also emphasised the vital role of pharmacists and pharmacies in the implementation of CYP2C19 genotype testing used to guide prescribed antiplatelet medication. According to the NICE guidance, pharmacists with their expertise in pharmacogenomics and patient medication management, will be integral in interpreting test results and recommending appropriate antiplatelet therapy. It also highlighted the need for close collaboration with other healthcare professionals to ensure effective implementation across various care settings for stroke patients. The diagnostics advisory committee, a standing advisory committee of NICE, agreed that it should be possible to gather samples for genotype testing at a location that is convenient for the person having the test and highlighted the role of pharmacies as accessible locations for CYP2C19 genotype testing.The National Institute for Health and Care Excellence (NICE) has published a new diagnostic guidance to enhance CYP2C19 genotype testing to guide clopidogrel use for patients who have suffered an ischemic stroke or transient ischemic attack. Published in July, the diagnostic guidance also emphasised the vital role of pharmacists and pharmacies in the implementation of CYP2C19 genotype testing used to guide prescribed antiplatelet medication. According to the NICE guidance, pharmacists with their expertise in pharmacogenomics and patient medication management, will be integral in interpreting test results and recommending appropriate antiplatelet therapy. It also highlighted the need for close collaboration with other healthcare professionals to ensure effective implementation across various care settings for stroke patients. The d

As winter approaches, healthcare experts are urging the public to support the NHS by embracing self-care and turning to pharmacies for minor ailments and injuries to help ease the strain on the healthcare system. New research from PAGB, the consumer healthcare association, has revealed that nearly a quarter of Brits still don't consider self-care as a first option for easy-to-treat conditions. The research found that many younger adults lack the confidence in self-care that older adults possess. About 23 per cent of those aged 25 to 34 admitted they would seek a GP appointment for minor ailment or injury they could treat themselves, compared to just nine per cent of those aged 65 or older. For common conditions, 56 per cent visit their GP for a UTI, 27 per cent for thrush, 20 per cent for acne and 20 per cent for conjunctivitis. Michelle Riddalls, CEO of PAGB, emphasised that while awareness of the benefits of self-care, for both consumers and the health service, has increased as a result of educational outreach and activities such as Self-Care Week (18th-24th November 2024), there is still significant room for improvement. The PAGB data shows that only 18 per cent of people could recall seeing a news story or campaign promoting self-care in the previous year, though this rises to 29per cent for young adults (ages 18-24).

A new report has highlighted that the public places a higher value on medicines for severe medical conditions, such as terminal cancer, than the thresholds currently used by the National Institute for Health and Care Excellence (NICE). The study, conducted by the Office of Health Economics (OHE), found a misalignment between NICE's current 'severity modifier'-which determines whether a medicine is recommended for coverage on the National Health Service (NHS)-and the UK public's preference for prioritising health gains for more severe diseases. The research, commissioned and funded by the Association of the British Pharmaceutical Industry (ABPI), also indicated that the public is willing to pay more for medicines used to treat patients with severe disease. Titled 'Understanding Societal Preferences for Priority by Disease Severity in England and Wales,' the report suggested that NICE's current severity modifier may be limiting access to innovative treatments for NHS patients. The ABPI has called on the government and NICE to adopt a more flexible approach when assessing medicines for severe conditions.

People are advised to be mindful of medications that may cause sun reactions, and to watch out for dodgy hay fever treatments and fake weight loss pens. For those traveling abroad, the MHRA advises considering the suitability of medicines available to reduce the risk of contracting tropical diseases. Dr Alison Cave, Chief Safety Officer at the MHRA, said: "The summer is an exciting time for many of us, as we take time off to travel and enjoy the warmer weather. "But it is important to understand what this time of year means for our medicines and medical devices, and take the precautions necessary to use products safely and protect ourselves." Watch out for dodgy hay fever treatments Millions of Britons suffer from hay fever symptoms in the summer. The MHRA advises consulting a healthcare professional to find the best treatment for your symptoms. People are also warned to be cautious of medicines advertised as hay fever treatments but not approved for use in the UK, such as Kenalog. This is a prescription-only steroid injection licensed as a medicine for other conditions, but not for the treatment of hay fever.

The MHRA on Wednesday granted a license for Eli Lilly's new Alzheimer's treatment, donanemab, for use in adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. However, the drug will not be available on the NHS, as the National Institute for Health and Care Excellence (NICE) concluded that it "does not currently demonstrate value for the NHS." The health spending watchdog explained that the costs of providing donanemab, including regular infusions and intensive monitoring for serious side effects, outweigh the relatively small benefits it offers to patients, and so it "cannot currently be considered good value for the taxpayer." Helen Knight, director of medicines evaluation at NICE, said: "For NICE to be able to approve a medicine for use in the NHS it must provide additional benefits to patients, and it must also represent a good use of NHS resources and taxpayers' money. Donanemab (also called Kisunla) is a monoclonal antibody drug given by infusion (through a drip in the arm). It targets and reduces beta-amyloid proteins, whose abnormal buildup is associated with Alzheimer's disease. Clinical trial evidence suggests that the monthly injection can slow Alzheimer's disease progression by 4 to 7 months.

Medical professionals often prescribe semaglutide to patients who have type 2 diabetes. Along with a balanced diet and regular exercise, it has also shown to be an incredibly efficient weight loss aid for patients. As the active ingredient in well-known brand-name drugs such as Wegovy, Ozempic, and Rybelsus, semaglutide is currently on everybody's lips. But what exactly is semaglutide? Does it really work for weight loss? We'll find an answer for you in this article, and explain the main benefits of using semaglutide for weight loss. What Is Semaglutide? A number of diabetic and weight loss medications, including Wegovy, Ozempic, and Rybelsus, have semaglutide as their active ingredient. This substance is a synthetic form of the hormone glucagon-like peptide-1 (GLP-1), that occurs naturally. Developed by the company Novo Nordisk, semaglutide was first approved by the FDA in 2017 as an injection for the treatment of adult type 2 diabetes (as part of the approval procedure for Ozempic). In 2019, the Food and Drug Administration approved a novel semaglutide form known as Rybelsus. Rybelsus was the first oral GLP-1 receptor agonist for the treatment of type 2 diabetes in the United States.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved lecanemab (Leqembi) for use in the early stages of Alzheimer's disease, following a thorough review of the drug's benefits and risks. Developed by Japanese pharmaceutical company Eisai, lecanemab is the first treatment for Alzheimer's disease licensed for use in Great Britain, with evidence indicating its potential to slow the disease's progression. Although the MHRA has granted a product license for the medicine, there are concerns about its cost and the potential delay before it becomes accessible to NHS patients. Pharmacist Thorrun Govind told Talk TV that the National Institute for Health and Care Excellence (NICE) is expected to make a final decision on its cost and availability by the end of the year. She highlighted that the drug is currently approved for private use, and that NICE will next evaluate it, weighing patient care against the value for taxpayers, with a final decision expected later this year.

The National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets (marketed as IQIRVO) for treating primary biliary cholangitis (PBC), a rare liver disease. Developed by Ipsen, IQIRVO is the first medicine for PBC approved for use on the NHS in nearly a decade. Elafibranor is indicated for use in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy for those who cannot tolerate UDCA. PBC is a lifelong condition that can worsen over time if inadequately treated, potentially leading to liver failure, the need for a liver transplant, or, in rare instances, premature death. Approximately 25,000 people in the UK are affected by PBC-90 per cent of whom are women. Early-stage PBC patients often suffer from severe fatigue and a persistent, debilitating itch known as pruritus.

The MHRA on Wednesday granted a license for Eli Lilly's new Alzheimer's treatment, donanemab, for use in adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. However, the drug will not be available on the NHS, as the National Institute for Health and Care Excellence (NICE) concluded that it "does not currently demonstrate value for the NHS." The health spending watchdog explained that the costs of providing donanemab, including regular infusions and intensive monitoring for serious side effects, outweigh the relatively small benefits it offers to patients, and so it "cannot currently be considered good value for the taxpayer." Helen Knight, director of medicines evaluation at NICE, said: "For NICE to be able to approve a medicine for use in the NHS it must provide additional benefits to patients, and it must also represent a good use of NHS resources and taxpayers' money. Donanemab (also called Kisunla) is a monoclonal antibody drug given by infusion (through a drip in the arm). It targets and reduces beta-amyloid proteins, whose abnormal buildup is associated with Alzheimer's disease.

Major health, care and research bodies, including the Department of Health and Social Care and the Office for National Statistics, should establish a national health data service in England to improve patient care and research - an NHS-commissioned review has recommended. Professor Cathie Sudlow's independent review of the UK health data landscape concluded that "complex and inefficient" data systems prevent and delay crucial analysis of health conditions affecting millions of people across the UK. The review - 'Uniting the UK's health data: a huge opportunity for society', published on 8 November 2024 - stressed the need for coordinated action across multiple organisations and stakeholders to ensure the greatest benefits for patients and the public from health-relevant data. They identified several barriers to using health data for public benefit and set our five recommendations for overcoming these barriers and transforming the national health data ecosystem. These include the establishment of a national health data service for England, embedded within existing organisational structures but with accountable senior leadership and a ring-fenced budget. Professor Sudlow said: "We are simply not maximising the benefits to society from the rich abundance of health data in the UK.

The Medicines and Healthcare products Regulatory Agency (MHRA) has awarded marketing authorisation to CStone Pharmaceuticals for sugemalimab (Eqjubi) as a first-line treatment for non-small cell lung cancer (NSCLC) in the UK. NSCLC is the most common form of lung cancer, accounting for around 80 to 85 out of 100 cases. Sugemalimab is now approved as a first-line treatment, in combination with platinum-based chemotherapy, for adult patients with metastatic NSCLC who do not have EGFR-sensitive mutations or ALK, ROS1, or RET genomic alterations. This UK approval follows its recent authorisation by the European Commission, marking the second international approval for sugemalimab. CStone's CEO Dr. Jason Yang described the UK's approval as a significant milestone in their global expansion strategy. "Sugemalimab is the first domestic anti-PD-L1 antibody to receive approval outside of China and has already entered the world's second-largest pharmaceutical market, the EU. "Now, with the UK approval, sugemalimab continued to expand its presence in the European market. The long-term survival data, recently presented at this year's ESMO Congress, further confirmed sugemalimab's value in the frontline treatment landscape for metastatic NSCLC," he said.

The National Pharmacy Association (NPA) is encouraging individuals to visit their local pharmacy for the treatment of minor ailments to avoid unnecessary days off from work, save the NHS money and improve patient care. A new NPA poll revealed that 55 per cent of workers missed at least one day of work last year due to coughs, colds, and other minor illnesses. The survey, which involved over 2,000 patients and was conducted by Research without Barriers, found that 31 per cent of respondents were absent from work for 1-6 days, 15 per cent for a week, 12 per cent for two weeks and 3 per cent for three weeks. This polling is part of the NPA's Ask Your Pharmacist Week campaign, which aims to dispel common myths around minor ailments and encourage greater use of local pharmacies for medical treatment. In England, pharmacies can now provide NHS treatments for a range of common ailments through the Pharmacy First Service, including ear infections, impetigo, shingles, sinusitis, sore throat, infected insect bites and uncomplicated urinary tract infections (UTIs). However, 36 per cent of people surveyed were unaware of the Pharmacy First service, with 20 per cent believing such ailments could only be treated by their GP.

With the UK General Election set for 4 July, pharmacy bodies are actively engaging with all political parties to secure support for the community pharmacy sector. They are pressing parties to address urgent issues such as pharmacy closures and medicine shortages. "The upcoming general election is a critical opportunity for us to strengthen supporters of community pharmacy in readiness for the new Parliament," said Janet Morrison, chief executive of Community Pharmacy England (CPE). She stressed the need for unity within the sector in advocating for community pharmacy and raising awareness of the issues with election candidates from all parties. As the general election approaches, CPE has called upon all political parties to support pharmacies by "introducing a long-term sustainable funding model and reviewing the medicines supply chain, including much-needed short-term relief measures."

The UK retail sector faced significant challenges in 2024, but 2025 is expected to be an even tougher year for retailers. Nearly 13,500 retail stores permanently shut their doors in the last 12 months -an average of 37 closures each day-according to provisional data from the Centre for Retail Research. This figure represents a notable 28.4 per cent increase from the 10,494 closures recorded in 2023, although it remains below the annual closure rates observed between 2019 and 2022. Independent retailers, typically small businesses with one to five stores, accounted for over 84 per cent of all closures during 2024. This marked a sharp 45 per cent surge in shutdowns for independents compared to the previous year when they were responsible for 74.5 per cent of closures, totalling 7,793 stores. The group's research director, Prof Joshua Bamfield told the Guardian: "The results for 2024 show that although the outcomes for store closures overall were not as poor as in either 2020 or 2022, they are still disconcerting, with worse set to come in 2025."

NHS England has reassured that GP Additional Roles Reimbursement Scheme funding will continue in 2025/26, encouraging primary care networks (PCNs) to use it for recruiting recently qualified GPs. In October 2024, updates to the Network Contract DES specification enabled PCNs to claim reimbursement for hiring recently qualified GPs through the ARRS for the remainder of 2024/25. An additional £82 million in funding was also announced to allow PCNs to employ over 1,000 additional GPs. This action is part of the government's strategy to boost long-term GP employment, helping practices offer more appointments for patients and addressing the issue of unemployment among newly qualified GPs. However, NHS England recognised that uncertainty about the continuation of ARRS funding beyond 2024/25 has been a barrier for some PCNs in undertaking recruitment of recently qualified GPs. To address this, Dr. Amanda Doyle, national director for primary care and community services at NHSE, issued an official statement reaffirming the continuation of this funding into 2025/26.

The newly-formed All-Party Parliamentary Group (APPG) for Life Sciences has written to Chancellor of the Exchequer Rachel Jane Reeves, urging her to protect and promote the life sciences sector in the government's first Budget. The group, which includes MPs and peers, convened for its first meeting in Parliament on Tuesday (15 October) to discuss the steps the Labour government should take to ensure that the UK remains a global leader in life sciences research and commercialisation. Following the meeting, the group sent a letter to the Chancellor, expressing their support for the Labour Party's life sciences strategy, A Prescription for Growth, which was published before the general election. They urged the Chancellor to maintain government funding for life sciences research and manufacturing, as well as the tax reliefs that encourage investment, in the Budget set for 30 October. Kit Malthouse MP, chair of the APPG, emphasised the potential of the life sciences sector, saying, "The Life Sciences sector holds out an incredible promise that the UK can be at the forefront of humanity's battle with disease and at the same time build a 21st century knowledge-based economy.

As the assisted dying bill moves through Parliament, pharmacy professionals are encouraged to take part in the public debate. The UK chief pharmaceutical officers (CPhOs) - Andrew Evans (Wales), Alison Strath (Scotland), Cathy Harrison (Northern Ireland), David Webb (England) - have issued advice for pharmacists and pharmacy technicians wishing to give their opinions on this important topic. "In our view it is entirely reasonable for any pharmacists and pharmacy technicians to give their opinions, and that the public would expect that," they said in a statement released along with Elizabeth Fidler, senior professional advisor for pharmacy technician practice at NHS England, and Richard Cattell, deputy chief pharmaceutical officer for England. However, pharmacy professionals are advised to avoid identifying individuals they have cared for unless with their consent and directly engaging patients in the debate. The guideline also emphasised that pharmacists and pharmacy technicians should express their personal views, and not speak for the professions. The CPhOs noted that the final decision on assisted dying must be made by society as a whole, through the parliamentary.

Pharmacy hub and spoke providers gathered at Westminster on Tuesday (November 19) to highlight to MPs the urgent need to implement Model One of Hub and Spoke legislation. This proposed model, aimed at making hub and spoke dispensing accessible to all pharmacies, was initially scheduled for rollout in January 2025, but has been delayed. Representatives from Centred Solutions, HubRx, and PillTime engaged with over 30 MPs at the event, which was organised with the support of former pharmacist and Labour MP Sadik Al-Hassan. They highlighted the significant benefits of hub and spoke for community pharmacies and stressed the need to extend its use across different legal entities. Sadik Al-Hassan, MP for North Somerset and officer for the Pharmacy APPG, expressed his support, saying, "Community pharmacies are a vital lifeline for our high streets and independents have always been at a disadvantage versus larger chains who can employ economies of scale. "Model One of the proposed legislation would allow the benefits of big pharmacies for smaller ones to help them focus on the service provision our NHS needs during this difficult financial time."

The government has accepted the Joint Committee on Vaccination and Immunisation's (JCVI) advice for the autumn 2024 COVID-19 vaccination programme. According to the JCVI, the following groups will be eligible for vaccination this autumn: Individuals aged 65 and over Residents of care homes for older adults Those aged 6 months and older in clinical risk groups Minister for Public Health and Prevention, Andrew Gwynne, emphasised the importance of protecting vulnerable populations from COVID-19 and reducing pressure on the NHS. He said: "We are committed to protecting those most vulnerable from COVID and have accepted the independent advice from the JCVI for the autumn 2024 vaccination programme." "I encourage anyone invited for a vaccine to get one as soon as possible to protect yourself and reduce pressure on the NHS during winter, helping to cut waiting times and get the health service back on its feet."

There is a clear opportunity for community pharmacists and their teams to lead best practice when it comes to supporting the ongoing health needs of older people. As the global population continues to age, the demand for specialised healthcare services tailored to the elderly is rapidly increasing. Community pharmacists, with their accessible locations and frequent interactions with patients, are uniquely positioned to play a pivotal role in addressing this growing need. The ageing population presents a complex set of health challenges, including multiple chronic conditions, polypharmacy, and increased susceptibility to adverse drug reactions. Community pharmacists, armed with their extensive knowledge of medications and their effects, can serve as the first line of defence in managing these issues. By leveraging their expertise, they can implement best practices that not only improve the quality of life for older individuals but also reduce the burden on the broader healthcare system. One of the primary areas where community pharmacists can make a significant impact is in medication management. As people age, they often find themselves taking multiple medications for various conditions. This polypharmacy can lead to dangerous drug interactions, side effects, and compliance issues. Community pharmacists can lead the way in implementing comprehensive medication reviews, ensuring that each patient's drug regimen is optimised for their specific needs and minimising potential risks.